trending Market Intelligence /marketintelligence/en/news-insights/trending/pf_4tkqlnpi7-tudkqlzgq2 content esgSubNav
In This List

Sanofi drops ImmunoGen cancer compound from product pipeline

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Sanofi drops ImmunoGen cancer compound from product pipeline

France's Sanofi removed SAR428926 from its product pipeline.

The pharmaceutical giant had acquired the anticancer compound from Waltham, Mass.-based ImmunoGen Inc. as part of a $30 million deal. The drug was still in its investigational phase.

Another investigational compound, GZ402668 for the treatment of multiple sclerosis patients whose disease returned, was also removed from the company's pipeline. Multiple sclerosis is a disease affecting the central nervous system.

Sanofi also removed three mid-stage drugs from its pipeline: SAR100842, to treat an autoimmune disease known as systemic sclerosis; SAR156597, to treat a type of chronic lung disease known as idiopathic pulmonary fibrosis; and isatuximab for acute lymphoblastic leukemia, a type of blood cancer.

Sanofi will continue to investigate isatuximab as a treatment for newly diagnosed multiple myeloma patients, however.

The company removed Patisiran to treat a genetic disorder. The decision was prompted after Sanofi tweaked its rare disease alliance with Alnylam Pharmaceuticals Inc.